Menu

Area Soci

Startup Name
Genenta Science

Website (URL)
www.genenta.com

Country
Italy

Italy province
Milano

City
Milano

TAX Code
08738490963

Ateco Code 2007
[21.20.09]

One line pitch
Hematopoietic-Stem-Cell Gene Therapy for Tumor Treatment

Short Description
Genenta develops a gene transfer strategy into autologous hematopoietic stem/progenitor cells (HSPCs) to target interferon-α expression to tumor-infiltrating monocytes/macrophages. An HIV-derived and genetically disabled viral vector - Lentivirus - delivers the gene into the HSPCs. The clinical use of interferon-α as a drug has been limited by its high toxicity. Thanks to Genenta’s innovative therapy, using a combination of transcriptional and microRNA-mediated control, tumor-infiltrating monocytes/macrophages (TEMs) become capable to selectively express interferon-αlimited to the tumor micro environment. Based on these mechanisms, TEMs are armed with a specific drug and can systematically break the tumor immune-tolerance reprogramming the micro environment and generate an immune response. Genenta raised USD 20 Million (Euro 17M) Series A+B Round of financing in March 2015 and September 2017.

Customer type
B2B

Local or global target
global

Funded
yes

Type of investors who funded this startup

  • Venture Capital

Incubated or Accelerated
no

Industry
Human health activities

Youtube Video

Bitnami